MeiraGTx (MGTX) to Release Quarterly Earnings on Wednesday

MeiraGTx (NASDAQ:MGTX) is expected to release its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect MeiraGTx to post earnings of ($0.51) per share and revenue of $7.7050 million for the quarter. Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Friday, November 21, 2025 at 12:30 PM ET.

MeiraGTx (NASDAQ:MGTX) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.04. MeiraGTx had a negative return on equity of 314.44% and a negative net margin of 415.39%.The business had revenue of $3.69 million during the quarter, compared to analysts’ expectations of $8.00 million. On average, analysts expect MeiraGTx to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MeiraGTx Stock Up 0.7%

MGTX stock opened at $8.47 on Monday. The business’s 50-day moving average price is $8.16 and its 200-day moving average price is $7.36. The stock has a market cap of $681.41 million, a P/E ratio of -4.15 and a beta of 1.35. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 26.29. MeiraGTx has a twelve month low of $4.55 and a twelve month high of $9.50.

Analysts Set New Price Targets

A number of research firms have weighed in on MGTX. Raymond James Financial began coverage on shares of MeiraGTx in a research report on Tuesday, October 21st. They issued a “strong-buy” rating and a $29.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of MeiraGTx in a research note on Wednesday, October 8th. Finally, Chardan Capital reiterated a “buy” rating and issued a $35.00 price target on shares of MeiraGTx in a research note on Friday, August 15th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $25.67.

Insider Activity

In related news, CFO Richard Giroux sold 24,000 shares of the business’s stock in a transaction dated Tuesday, October 21st. The stock was sold at an average price of $8.87, for a total value of $212,880.00. Following the sale, the chief financial officer directly owned 829,494 shares in the company, valued at approximately $7,357,611.78. The trade was a 2.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Alexandria Forbes sold 47,500 shares of the stock in a transaction that occurred on Tuesday, October 7th. The shares were sold at an average price of $8.39, for a total value of $398,525.00. Following the transaction, the chief executive officer directly owned 1,313,983 shares of the company’s stock, valued at approximately $11,024,317.37. The trade was a 3.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 7.50% of the stock is owned by corporate insiders.

Institutional Trading of MeiraGTx

A number of large investors have recently added to or reduced their stakes in MGTX. Perceptive Advisors LLC lifted its position in MeiraGTx by 0.4% during the second quarter. Perceptive Advisors LLC now owns 12,626,103 shares of the company’s stock valued at $82,231,000 after purchasing an additional 45,000 shares during the last quarter. Balyasny Asset Management L.P. bought a new stake in shares of MeiraGTx in the 2nd quarter worth about $919,000. Bank of America Corp DE raised its position in shares of MeiraGTx by 493.8% during the 2nd quarter. Bank of America Corp DE now owns 266,666 shares of the company’s stock valued at $1,739,000 after buying an additional 221,755 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in shares of MeiraGTx by 7.1% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 6,034,578 shares of the company’s stock valued at $39,345,000 after acquiring an additional 400,000 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in MeiraGTx by 142.9% in the third quarter. JPMorgan Chase & Co. now owns 60,394 shares of the company’s stock worth $497,000 after acquiring an additional 35,527 shares in the last quarter. Institutional investors own 67.48% of the company’s stock.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.